Anti hla dr bv605

Manufactured by BioLegend

Anti-HLA-DR-BV605 is a fluorochrome-conjugated monoclonal antibody that binds to the HLA-DR antigen, which is expressed on the surface of antigen-presenting cells, including B cells, monocytes, and dendritic cells. This product is suitable for flow cytometric analysis of HLA-DR expression on these cell types.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

HLA-DR (94 citations) Anti-HLA-DR (38 citations) HLA-DR BV605 (6 citations)

2 protocols using anti hla dr bv605

Tetramer-Based Enrichment of Antigen-Specific T Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs (2.4–10 × 10⁶) were stained with WT HLA-A2^S269–277-PE and variant HLA-A2^S269–277-APC tetramers at room temperature for 1 h in MACS buffer (PBS with 0.5% BSA and 2 mM EDTA). Cells were then incubated with anti-PE and anti-APC microbeads (Miltenyi Biotec), and tetramer⁺ cells were enriched using magnetic separation (9 (link)). Lymphocytes were stained with anti-CD71-BV421 (#562995), anti-CD4-BV650 (#563875), anti-CD27-BV711 (#563167), anti-CD38-BV786 (#563964), anti-CCR7-AF700 (#561143), anti-CD14-APC-H7 (#560180), anti-CD19-APC-H7 (#560177), anti-CD45RA-FITC (#555488), anti-CD8-PerCP-Cy5.5 (#565310), anti-CD95-PE-CF594 (#562395), anti-PD1-PE-Cy7 (#561272) (BD Biosciences), anti-CD3-BV510 (#317332), anti-HLA-DR-BV605 (#307640) (BioLegend), and LIVE/DEAD near-infrared stain (#L10119, Invitrogen) for 30 min, fixed with 1% PFA before acquiring data on an LSRII Fortessa (BD Bioscience). FCS files were analyzed using FlowJo v10 software.

Chaurasia P., Nguyen T.H., Rowntree L.C., Juno J.A., Wheatley A.K., Kent S.J., Kedzierska K., Rossjohn J, & Petersen J. (2021). Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. The Journal of Biological Chemistry, 297(3), 101065.

+ Open protocol

+ Expand

Comprehensive Immunophenotyping of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-CD19 APC-Cy7, anti-CD38 PerCp-Cy5.5, anti-CD4 PE-Cy7, anti-CD25 PerCP-Cy5.5, anti-CD86 APC, anti-CD80 BV421, anti-CD45RA BV605, anti-ICOS PE, anti-CD21 PE-Cy7, anti-CD80 BV421, anti-CD27 PerCp-Cy5.5, anti-PD-1 APC, anti-CD45RA APC-Cy7, anti-HLA-DR BV605, anti-CD11c AF700, anti-CD86 BV711, anti-CD95 BV650, anti-IgD BV786, anti-FCRL5 APC, anti-CXCR3 BV421, anti-CCR6 BV605, anti-CD19 BV650, anti-CD19 BV605, anti-PD-L1 BV421, anti-PD-L2 PE, anti-ICOS-L PE, anti-OX40L PE, anti-IL-10 PE, anti-IL-10 APC, anti-TNF-α APC-Cy7 (all obtained from BioLegend); anti-IgD FITC and anti-IgD PE (both from Southern Biotech); anti-CD27 PE (Dako); and anti-CD21 PE-Cy7, anti-CD69 FITC, anti-HLA-DR FITC, anti-CD27 BV605, anti-CD40 FITC, anti-CD40L PE, anti-ICAM-1 PE, anti-CXCR5 BUV395 and anti-CD27 BUV395 (all from BD Biosciences).

Reincke M.E., Payne K.J., Harder I., Strohmeier V., Voll R.E., Warnatz K, & Keller B. (2020). The Antigen Presenting Potential of CD21low B Cells. Frontiers in Immunology, 11, 535784.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!